Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ovarian cancer. It also develops BA3021, a CAB ADC for multiple solid tumor types, including NSCLC, melanoma, and ovarian cancer; and BA3071, which is a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for renal cell carcinoma, NSCLC, small cell lung cancer, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer, and cervical cancer. BioAtla, Inc. was founded in 2007 and is based in San Diego, California.

BioAtla, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

CONTEXT ANNOUNCES BUYOUT OF CT-202 FUTURE MILESTONES AND ROYALTIES IN EXCHANGE FOR A FULLY PAID-UP, NON-TERMINABLE LICENSE

CONTEXT THERAPEUTICS ENTERS INTO LICENSE AGREEMENT AMENDMENT WITH BIOATLA FOR CT-202

SAN DIEGO, MARCH 31, 2026 (GLOBE NEWSWIRE) -- BIOATLA, INC. (NASDAQ: BCAB OR THE COMPANY), A GLOBAL CLINICAL-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON THE DEVELOPMENT OF CONDITIONALLY ACTIVE BIOLOGIC (CAB) ANTIBODY THERAPEUTICS FOR THE TREATMENT OF SOLID TUMORS, TODAY ANNOUNCED THAT IT WILL EFFECT A 50-FOR-1 SHARE CONSOLIDATION (THE SHARE CONSOLIDATION) OF ITS COMMON STOCK, PAR VALUE $0.0001 PER SHARE (THE COMMON STOCK), THAT IS EXPECTED TO BECOME EFFECTIVE ON APRIL 6, 2026 AT 12:01 A.M. EASTERN TIME (THE EFFECTIVE DATE). THE COMMON STOCK WILL CONTINUE TO TRADE ON THE NASDAQ CAPITAL MARKET UNDER THE EXISTING SYMBOL BCAB AND IS EXPECTED TO BEGIN TRADING ON A SPLIT-ADJUSTED BASIS WHEN THE MARKET OPENS ON APRIL 6, 2026. FOLLOWING THE SHARE CONSOLIDATION, THE NEW CUSIP NUMBER FOR THE COMMON STOCK WILL BE 09077B203.

BIOATLA ANNOUNCES SHARE CONSOLIDATION

INITIATED A FORMAL PROCESS TO MONETIZE ASSETS IMPLEMENTED A RESTRUCTURING PLAN TO SIGNIFICANTLY REDUCE OPERATING EXPENSES AND EXTEND RUNWAY SAN DIEGO, MARCH 31, 2026 (GLOBE NEWSWIRE) -- BIOATLA, INC. (NASDAQ: BCAB), A GLOBAL CLINICAL-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON THE DEVELOPMENT OF CONDITIONALLY ACTIVE BIOLOGIC (CAB) ANTIBODY THERAPEUTICS FOR THE TREATMENT OF SOLID TUMORS, TODAY ANNOUNCED ITS FINANCIAL RESULTS FOR THE FULL YEAR AND FOURTH QUARTER ENDED DECEMBER 31, 2025 AND PROVIDED BUSINESS HIGHLIGHTS. AS WE EVALUATE STRATEGIC PATHS FORWARD, OUR FOCUS REMAINS ON SUPPORTING THE ADVANCEMENT OF THE ONGOING PHASE 1 STUDY OF BA3182 IN ADENOCARCINOMAS, WHILE PRESERVING CAPITAL, AND ENSURING WE MAINTAIN THE FLEXIBILITY TO PURSUE ALL POTENTIAL VALUECREATING OPTIONS, SAID JAY M.

BIOATLA REPORTS FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS AND BUSINESS HIGHLIGHTS

SAN DIEGO, MARCH 02, 2026 (GLOBE NEWSWIRE) -- BIOATLA, INC. (NASDAQ: BCAB OR THE COMPANY), A GLOBAL CLINICAL-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON THE DEVELOPMENT OF CONDITIONALLY ACTIVE BIOLOGIC (CAB) ANTIBODY THERAPEUTICS FOR THE TREATMENT OF SOLID TUMORS, ANNOUNCED THAT THE BOARD OF DIRECTORS HAS INITIATED A FORMAL PROCESS TO EXPLORE AND EVALUATE STRATEGIC OPTIONS TO MAXIMIZE SHAREHOLDER VALUE, INCLUDING THE SALE OF PRECLINICAL AND CLINICAL ASSETS, LICENSING TRANSACTIONS, STRATEGIC PARTNERSHIPS OR OTHER CORPORATE TRANSACTIONS. CONCURRENTLY, THE COMPANY IS IMPLEMENTING A RESTRUCTURING PLAN TO SIGNIFICANTLY REDUCE OPERATING EXPENSES, INCLUDING A WORKFORCE REDUCTION OF APPROXIMATELY 70% AND EXPANSION OF OUR COST-CONTAINMENT MEASURES. THE COMPANY INTENDS TO RETAIN ALL EMPLOYEES ESSENTIAL FOR SUPPORTING VALUE CREATION AS PART OF ITS STRATEGIC REVIEW.

BIOATLA ANNOUNCES FORMAL PROCESS TO EVALUATE STRATEGIC OPTIONS TO MONETIZE ASSETS

SAN DIEGO, DEC. 31, 2025 (GLOBE NEWSWIRE) -- BIOATLA, INC. (NASDAQ: BCAB), A GLOBAL CLINICAL-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON THE DEVELOPMENT OF CONDITIONALLY ACTIVE BIOLOGIC (CAB) ANTIBODY THERAPEUTICS FOR THE TREATMENT OF SOLID TUMORS, AND GATC HEALTH CORP. (GATC), A TECH-BIO COMPANY LEVERAGING ARTIFICIAL INTELLIGENCE (AI) TO TRANSFORM DRUG DISCOVERY AND DEVELOPMENT, TODAY ANNOUNCED A SPV TRANSACTION TO ADVANCE OZURIFTAMAB VEDOTIN (OZ-V) (CAB-ROR2-ADC) IN A PHASE 3 STUDY IN 2L+ OROPHARYNGEAL SQUAMOUS CELL CARCINOMA (OPSCC).

BIOATLA AND GATC HEALTH ANNOUNCE A $40 MILLION SPECIAL PURPOSE VEHICLE (SPV) TRANSACTION TO ADVANCE OZURIFTAMAB VEDOTIN (OZ-V) INTO A REGISTRATIONAL TRIAL FOR 2L+ OROPHARYNGEAL SQUAMOUS CELL CARCINOMA (OPSCC)

SAN DIEGO, NOV. 21, 2025 (GLOBE NEWSWIRE) -- BIOATLA, INC. (NASDAQ: BCAB), A GLOBAL CLINICAL-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON THE DEVELOPMENT OF CONDITIONALLY ACTIVE BIOLOGIC (CAB) ANTIBODY THERAPEUTICS FOR THE TREATMENT OF SOLID TUMORS, TODAY ANNOUNCED THAT IT HAS ENTERED INTO PRE-PAID ADVANCE AGREEMENTS WITH AN AFFILIATE OF YORKVILLE ADVISORS GLOBAL (YORKVILLE) AND FUNDS MANAGED BY OF ANSON ADVISORS INC. TO PROVIDE AN AGGREGATE $7.5 MILLION ADVANCE TO THE COMPANY. BIOATLA ALSO ENTERED INTO A STANDBY EQUITY PURCHASE AGREEMENT IN WHICH YORKVILLE HAS A COMMITMENT TO BUY, IF THE COMPANY EXERCISES ITS OPTION, FOR UP TO A TOTAL OF $15 MILLION OF COMMON STOCK AT A 3% DISCOUNT TO THE THEN CURRENT MARKET PRICES OVER THREE YEARS, SUBJECT TO CERTAIN CONDITIONS.

BIOATLA ENTERS INTO AGREEMENTS FOR UP TO $22.5 MILLION FLEXIBLE FINANCING

COMPANY ACHIEVED FDA ALIGNMENT ON PHASE 3 OZ-V TRIAL FOR THE TREATMENT OF 2L+ OPSCC, WHICH WILL EVALUATE DUAL PRIMARY ENDPOINTS WITH POTENTIAL OF ACHIEVING ACCELERATED APPROVAL FOLLOWED BY FULL APPROVAL COMPANY IS IN ADVANCED STAGES TO FINALIZE A STRATEGIC TRANSACTION WITH A POTENTIAL PARTNER AND WE REMAIN ON TRACK TO COMPLETE THE TRANSACTION BY YEAR END BA3182 TRIAL IN ADVANCED ADENOCARCINOMAS IS CURRENTLY ONGOING AND EVALUATING VARIOUS DOSING AND TREATMENT SCHEDULES WITH A READOUT EXPECTED IN THE FIRST HALF OF 2026 ACHIEVED MILESTONE WITH CONTEXT THERAPEUTICS UNDER THE LICENSE AGREEMENT FOR THE CAB-NECTIN4-TCE REFLECTING CONTINUED PROGRESS AND VALIDATION OF BIOATLA'S DIFFERENTIATED CAB T-CELL ENGAGER PLATFORM MANAGEMENT TO HOST A CONFERENCE CALL AND WEBCAST TODAY AT 4:30 P.M. EASTERN TIME SAN DIEGO, NOV. 13, 2025 (GLOBE NEWSWIRE) -- BIOATLA, INC. (NASDAQ: BCAB), A GLOBAL CLINICAL-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON THE DEVELOPMENT OF CONDITIONALLY ACTIVE BIOLOGIC (CAB) ANTIBODY THERAPEUTICS FOR THE TREATMENT OF SOLID TUMORS, TODAY ANNOUNCED ITS FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2025 AND PROVIDED HIGHLIGHTS ON ITS CLINICAL PROGRAMS.

BIOATLA REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS AND HIGHLIGHTS RECENT PROGRESS

 MEC-V DEMONSTRATES MEDIAN OS OF 21.5 MONTHS IN PATIENTS WITH TREATMENT-REFRACTORY LEIOMYOSARCOMA, LIPOSARCOMA, AND UNDIFFERENTIATED PLEOMORPHIC SARCOMA COMPARED WITH APPROXIMATELY 12 MONTHS WITH APPROVED AGENTS

BIOATLA'S MECBOTAMAB VEDOTIN (MEC-V), AN AXL-TARGETING ADC, DEMONSTRATES A MEDIAN OVERALL SURVIVAL (OS) OF 21.5 MONTHS IN SUBTYPES OF REFRACTORY SOFT TISSUE SARCOMAS

SAN DIEGO, NOV. 05, 2025 (GLOBE NEWSWIRE) -- BIOATLA, INC. (NASDAQ: BCAB), A GLOBAL CLINICAL-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON THE DEVELOPMENT OF CONDITIONALLY ACTIVE BIOLOGIC (CAB) ANTIBODY THERAPEUTICS FOR THE TREATMENT OF SOLID TUMORS, TODAY ANNOUNCED THAT IT PLANS TO HOST A CONFERENCE CALL AND WEBCAST ON THURSDAY, NOVEMBER 13, 2025 AT 4:30 P.M. ET TO DISCUSS ITS FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2025 AND PROVIDE BUSINESS HIGHLIGHTS.

BIOATLA TO ANNOUNCE THIRD QUARTER 2025 FINANCIAL RESULTS AND PROVIDE BUSINESS HIGHLIGHTS ON NOVEMBER 13, 2025

SAN DIEGO, OCT. 23, 2025 (GLOBE NEWSWIRE) -- BIOATLA, INC. (NASDAQ: BCAB), A GLOBAL CLINICAL-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON THE DEVELOPMENT OF CONDITIONALLY ACTIVE BIOLOGIC (CAB) ANTIBODY THERAPEUTICS FOR THE TREATMENT OF SOLID TUMORS, TODAY ANNOUNCED PRESENTATION OF A POSTER ENTITLED TARGETING HPV E6/E7 UPREGULATION OF THE TRANSMEMBRANE RECEPTOR TYROSINE KINASE ROR2 WITH THE ADC OZURIFTAMAB VEDOTIN IN PATIENTS WITH ADVANCED HPV+ OROPHARYNGEAL SQUAMOUS CELL CARCINOMA WHICH DETAILS CLINICAL DATA FROM ITS INVESTIGATIONAL ANTIBODY-DRUG CONJUGATE (ADC), OZURIFTAMAB VEDOTIN (OZ-V), AT THE INTERNATIONAL PAPILLOMAVIRUS SOCIETY (IPVS) CONFERENCE, TAKING PLACE OCTOBER 2326, 2025, IN BANGKOK, THAILAND.

BIOATLA PRESENTS COMPELLING MECHANISTIC RATIONALE FOR TARGETING ROR2 WITH OZURIFTAMAB VEDOTIN (OZ-V) IN OROPHARYNGEAL SQUAMOUS CELL CARCINOMA (OPSCC) AT THE ANNUAL CONFERENCE OF THE INTERNATIONAL PAPILLOMAVIRUS SOCIETY

BioAtla, Inc.

BCAB

Price

Financial Reports

No items found.

Press Releases

BioAtla, Inc.

BCAB.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

BCAB